A priority review designation is granted to drugs that, if approved, have the potential to offer significant improvement compared to marketed products or provide a treatment where no adequate therapy exists.
The FDA has assigned dolutegravir a Prescription Drug User Fee Act target date of 17 August.
The new drug application for dolutegravir was received by the FDA on 17 December, and includes the results of four pivotal phase III clinical trials that treated a total of 2553 patients with HIV/AIDS across the treatment spectrum, from therapy naÃ¯ve to salvage patients.
Dolutegravir is in development and subject to evaluation of the benefits and risks by the regulatory authorities before it can be approved and made available on prescription.
ViiV Healthcare submitted a marketing authorisation application for dolutegravir to the European Medicines Agency (EMA) on 17 December.
At 3:24pm: [LON:GSK] GlaxoSmithKline share price was +7.75p at 1472.75p
Story provided by StockMarketWire.com